RecruitingEarly Phase 1NCT06853145

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis


Sponsor

University of Virginia

Enrollment

6 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Able to provide informed consent 18 years of age or greater Clinical diagnosis of IPF

Exclusion Criteria8

  • Continuous oxygen use at home
  • Oxygen saturation less than 92% on the day of MRI procedure
  • Pregnancy or lactation
  • Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
  • History of congenital cardiac disease, chronic renal failure, or cirrhosis. • Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches.
  • Inability to understand simple instructions or to hold still for approximately 10-15 seconds.
  • History of respiratory infection within 2 weeks prior to the MR scan
  • History of MI, stroke and/or poorly controlled hypertension.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHyperpolarized Xe129

Hyperpolarized Xe129-MRI: Patients will undergo hyperpolarized Xe129-MRI at the University of Virginia Radiology Imaging Core (Charlottesville, VA, USA). The entire procedure visit takes approximately 3 hours based on our team's experience.


Locations(1)

Snyder Building 480 Ray C. Hunt Drive

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06853145


Related Trials